In a Phase 1/2 trial MRTX849, an investigational KRAS G12C inhibitor has demonstrated clinical activity, including objective responses in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). Although a maximum targeted dose has not yet been...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok
